ESMO22 -LBA10 - Sotorasib vs docetaxel for previously treated NSCLC with KRAS G12C mutation - Co...

preview_player
Показать описание
recorded @ ESMO Press Briefing, Monday, September 12
  1. Oncoletter
Рекомендации по теме
ESMO22 -LBA10 - 0:04:31

ESMO22 -LBA10 - Sotorasib vs docetaxel for previously treated NSCLC with KRAS G12C mutation - Co...

#ESMO22 Highlights on 0:02:35

#ESMO22 Highlights on Sotorasib in NSCLC with KRAS G12C mutation: The CodeBreaK 200 study

Highlights on sotorasib 0:04:09

Highlights on sotorasib plus panitumumab in KRAS G12C-mutated mCRC: The CodeBreak 300 study

#ESMO22 Highlights on 0:03:35

#ESMO22 Highlights on actionable inflammatory axis for air pollution induced NSCLC

CodeBreaK 200: sotorasib 0:02:42

CodeBreaK 200: sotorasib versus docetaxel in pretreated KRAS G12C-mutant NSCLC

#ESMO22 Highlights on 0:02:21

#ESMO22 Highlights on ADT duration with post-operative radiotherapy in prostate cancer: RADICALS-HD

#ESMO22 Highlights on 0:02:30

#ESMO22 Highlights on first-line atezolizumab in NSCLC not eligible for platinum: The IPSOS study

Sotorasib demonstrates superior 0:05:36

Sotorasib demonstrates superior PFS vs docetaxel for previously treated non-small cell lung canc...

Sotorasib drug-drug interactions 0:02:15

Sotorasib drug-drug interactions

Sotorasib,FDA,Lumakras amgen 510,non-small 0:04:20

Sotorasib,FDA,Lumakras amgen 510,non-small cell lung cancer

ASCO 2021 Lung 0:05:26

ASCO 2021 Lung Recap: CodeBreak 100: Sotorasib in KRAS G12C Mutation

Phase II CodeBreak 0:03:01

Phase II CodeBreak 100 trial of sotorasib in advanced NSCLC

Sotorasib outperforms docetaxel 0:02:59

Sotorasib outperforms docetaxel in previously treated KRAS-mutated NSCLC | Melissa Johnson

Sotorasib achieved clinically 0:02:29

Sotorasib achieved clinically meaningful activity in KRAS G12C-mutated advanced pancreatic cancer

Cobertura Pós ESMO 2:19:21

Cobertura Pós ESMO 2022 20/09/2022

16-Sotorasib for Lung 0:29:07

16-Sotorasib for Lung Cancers with KRAS p.G12C Mutation

Tumore del polmone 0:03:25

Tumore del polmone KRAS G12C, dati importanti su sotorasib

Statement ESMO 2022 0:01:22

Statement ESMO 2022 Highlights Lung Cancer - Prof. Dr. med. Miklos Pless, Winterthur

Tumore del polmone, 0:05:54

Tumore del polmone, via libera europeo per sotorasib, primo anti-KRAS

Air pollution and 0:01:57

Air pollution and EGFRm lung cancer: pathway identified

Lung Cancer Webinar 1:02:46

Lung Cancer Webinar Series on The Treatment of KRAS

ASCO2022 - LBA1: 0:07:46

ASCO2022 - LBA1: Panitumumab + mFOLFOX6 vs bevacizumab plus mFOLFOX6 1st-line in RAS WT mCRC (P...

David S. Hong, 0:01:43

David S. Hong, MD, speculates on the next steps in the development of sotorasib (AMG 510)

Myriam Chalabi, ESMO 0:07:29

Myriam Chalabi, ESMO 2022: Neoadjuvant immune checkpoint inhibition in MMR-deficient colon cancer